Preview

Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice

Advanced search

Pharmacoeconomic aspects of the diabetic ketoacidosis prevention in type 1 diabetes mellitus by self-monitoring of blood ketones

Abstract

Diabetic ketoacidosis (DKA) is one of the most serious acute complications observed with a frequency of 10-100 cases per year per 1000 patients with type 1 diabetes mellitus (DM1). More than a third of patients with DKA are admitted to hospital in diabetic coma state (DC) with mortality of 19%. In spite of the serious complications and the high social importance, the problem of preventing the DKA has received little attention. Objective: To evaluate the epidemiology of the DKA and pharmacoeconomic aspects of monitoring blood ketones at home, as one of the measures of prevention of diabetic ketoacidosis in patients with type 1 diabetes in Russia. Materials and methods. A literature search was conducted among national and international databases. Direct medical costs for treatment of the DKA and DC were studied in several hospitals of the Russian Federation. Cost-eff ectiveness of preventing the DKA for the public health system was evaluated. Results. Over 2.05 thousands of children’s and adolescents, and 14.9 thousand of adults with DM1 and the DKA are hospitalized annually in the Russian Federation, 0.62 and 7.47 thousands respectively in a state of DC that leads to a total cost of hospitalization of 63.8 millions, and 528.6 millions rubles, respectively. Monitoring of ketone bodies at home is one of the main methods for the prevention of DKA. Two methods for detecting ketosis are currently available in the Russian Federation: blood β-hydroxybutyrate testing and urine acetoacetate testing. Measurement of β-ketones in the blood as an accurate indicator of the amount of ketones in the microcirculation, shows the level of ketones in the blood at the present moment, allows adjust therapy and almost twice reduces the need for hospitalization, that may lead to a reduction in the annual cost of treatment of DKA and DC in hospitals by almost 300 million rubles in Russia. Conclusions. Th e widespread introduction of measuring β-ketones in the blood in routine practice for patients with DM1 will greatly reduce the number of hospitalizations and deaths due to diabetic ketoacidosis, as well as healthcare costs associated with this condition.

About the Authors

E. E. Petryaykina
GBUZ «Morozov Children’s Clinical Hospital, Department of Health of the city of Moscow», Moscow
Russian Federation


D. Yu. Belousov
LLC "Center for Pharmacoeconomics Research", Moscow
Russian Federation


I. I. Rybkina
GBUZ «Morozov Children’s Clinical Hospital, Department of Health of the city of Moscow», Moscow
Russian Federation


I. E. Koltunov
GBUZ «Morozov Children’s Clinical Hospital, Department of Health of the city of Moscow», Moscow
Russian Federation


References

1. Результаты реализации подпрограммы «Сахарный диабет» Федеральной целевой программы «Предупреждение и борьба с социально значимыми заболеваниями 2007–2012 годы». Сахарный диабет. 2013; (Спецвыпуск): 1–48.

2. Дедов И.И., Кураева Т.Л., Петеркова В.А. Сахарный диабет у детей и подростков. Руководство для врачей. М.: Гэотар-Медиа. 2007: 8–91.

3. Дедов И.И., Кураева Т.Л., Петеркова В.А., Емельянов А.О. Эпидемиологические исследования сахарного диабета 1 типа в детском возрасте в Европе. Сахарный диабет. 2005; (3): 2–6.

4. Дедов И.И., Кураева Т.Л., Петеркова В.А., Щербачёва Л.Н. Сахарный диабет у детей и подростков. Руководство для врачей. М.: Универсум Паблишинг, 2002: 15–23, 201–222.

5. Дедов И.И., Петеркова В.А. Детская эндокринология. Руководство для врачей. М.: Универсум Паблишинг, 2006: 479–587.

6. Дедов И.И., Кураева Т.Л., Петеркова В.А., Ремизов О.В., Титович Е.В. Генетические аспекты исследования и профилактики сахарного диабета у детей и подростков. Министерство здравоохранения и социального развития Российской Федерации. Пособие для врачей. М.: Медицина для Вас. 2004: 14–52.

7. Распоряжение Правительства РФ от 24.12.2012 № 2511-р «Об утверждении Государственной программы Российской Федерации «Развитие Здравоохранения».

8. Brown T.B. Cerebral oedema in childhood diabetic ketoacidosis: Is treatment a factor? Emerg. Med. J. 2004; 21: 141–144.

9. Edge J.A., Jakes R.W., Roy Y., Hawkins M., Winter D., Ford-Adams M.E., Murphy N.P., Bergomi A., Widmer B., Dunger D.B. Th e UK case-control study of cerebral oedema complicating diabetic ketoacidosis in children. Diabetologia. 2006; 49: 2002–2009.

10. Александрович Ю.С., Пшениснов К.В., Гордеев В.И. Интенсивная терапия диабетического кетоацидоза у детей. Российский вестник детской хирургии, анестезиологии и реаниматологии. 2012; 2 (Т.2): 92–99.

11. Султанова Л.М., Гайсина Л.Р., Шайдуллина М.Р. Диагностика и лечение кетоацидоза при сахарном диабете у детей. РМЖ. 2008; 3 (27): 43–45.

12. Weber C., Kocher S., Neeser K., Joshi S.R. Prevention of diabetic ketoacidosis and self-monitoring of ketone bodies: an overview. Current medical research and opinion. 2009 May;25(5):1197-207. Epub 2009/03/31.

13. Dunger D.B., Sperling M.A., Acerini C.L., Bohn D.J., Daneman D., Danne T.P., et al. ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents. Archives of disease in childhood. 2004 Feb; 89(2):188-94.

14. Wright J., Ruck K., Rabbitts R., Charlton M., De P., Barrett T. et al. Diabetic ketoacidosis (DKA) in Birmingham, UK, 2000–2009: an evaluation of risk factors for recurrence and mortality. Br J Diabetes Vasc Dis2009; 9: 278–282.

15. Hex N., Bartlett C., Wright D., Taylor M., Varley D. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabetic medicine: a journal of the British Diabetic Association. 2012 Jul; 29(7):855–62.

16. Bismuth E., Laff el L. Can we prevent diabetic кetoacidosis in children? Pediatric Diabetes. 2007; 8 (6): 24–33.

17. Maldonado M.R., Chong E.R., Oehl M.A., Balasubramanyam A. Economic impact of diabetic ketoacidosis in a multiethnic indigent population: analysis of costs based on the precipitating cause. Diabetes Care. 2003; 26: 1265–1269.

18. Приложение к приказу МЗ РФ № 163 от 27.05.2002 «Отраслевой стандарт. Система стандартизации в здравоохранении РФ. Клинико-экономические исследования. Общие положения».

19. Доклад о реализации Программы государственных гарантий оказания гражданам Российской Федерации бесплатной медицинской помощи в 2012 году.

20. Петряйкина Е.Ф. Неотложные и критические состояния при сахарном диабете у детей и подростков. Диссертация на соискание ученой степени доктора медицинских наук. М., 2012.

21. Тишковский С.В., Никонова Л.В., Гулинская О.В., Мартинкевич О.Н. Диабетический кетоацидоз: Этиопатогенез, анализ заболеваемости и поиск путей профилактики. Журнал Гродненского Государственного Медицинского Университета. 2011; 1: 82–84.

22. SEARCH for Diabetes in Youth Study Group, Liese AD, Agostino RB et al. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics. 2006; 118: 1510–1518.

23. Laff el L.M., Wentzell K., Loughlin C., et al. Sick day management using blood 3-hydroxybutyrate (3-OHB) compared with urine ketone monitoring reduces hospital visits in young people with T1DM: a randomized clinical trial. Diabet Med 2006; 23(3): 278–84.


Review

For citations:


Petryaykina E.E., Belousov D.Yu., Rybkina I.I., Koltunov I.E. Pharmacoeconomic aspects of the diabetic ketoacidosis prevention in type 1 diabetes mellitus by self-monitoring of blood ketones. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2014;(2):58-65. (In Russ.)

Views: 1203


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2588-0519 (Print)
ISSN 2618-8473 (Online)

  

OSZAR »